


Listing of Claims/Amendments

Please amend the claims to read as follows:

Claims 1-60 (previously canceled)

Claim 61 (previously presented): A compound of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein:

R^1 is H, alkyl, haloC₁-C₆ alkyl, cycloalkyl, cycloalkylNH-, arylalkyl, heterocycloalkyl, heteroaryl, N(R²)₂, or NR²aryl, unsubstituted aryl or aryl substituted with one to three X;

R^2 is the same or different in each occurrence and is independently selected from H or C₁-C₆ alkyl;

R^3 is H, C₁-C₆ alkyl, Cl, F, CF₃, OCF₂H, OCF₃, OH or C₁-C₆ alkoxy;

R^4 is H, C₁-C₆ alkyl, C₁-C₆ alkoxy, cycloalkyl, alkenyl, aryl, benzyl, arylNH-, cycloalkylNH-, N(R²)₂, or NR²aryl, said alkyl, alkoxy, cycloalkyl, alkenyl, or aryl optionally substituted with one to three X;

R^5 is H or C₁-C₆ alkyl;

R^6 is H or C₁-C₆ alkyl; or


R^5 and R^6 taken together with the carbon atom to form a carbonyl group;


L^1 is -S(O₂)-, -S(O)-, or -S-;

L^2 is -S(O₂)-, -S(O)-, or -S-;

X is the same or different, and is independently selected from H, halogen, CF₃, CN, OCF₂H, OCF₂CF₃, OCF₃, OR², C₁-C₆ alkyl, cycloalkyl, cycloalkoxy, C₁-

C₆ alkoxy, alkoxyC₁-C₆ alkoxy, O-cycloalkyl, cycloalkylamino, cycloalkylalkoxy, heteroalkyl, -OSO₂R², -COOR², -CON(R²)₂, NHR², arylNH-, N(R²)₂, or NR² aryl;

Y is a covalent bond, -CH₂-, -S(O₂)-, or  ;

Z is a covalent bond, -CH₂-, -S(O₂)- or  ; or

Y, R¹, Z and R² can be taken together with the nitrogen atom to form a heterocycloalkyl; with the proviso that if Y is a covalent bond, R¹ cannot form a N-N bond with the nitrogen atom; and

n is an integer of 0 to 4,

with the proviso that, when R¹ = R² = H or lower alkyl, Y=Z= covalent bond, n=0 or R³ at each occurrence is H, L¹ = L² = S or -S(O₂)-, X=H, and R⁴ is unsubstituted C₁-C₆ alkyl or phenyl substituted once with -CON(H)₂ or -CON(Me)₂, then R⁵ and R⁶ are each independently H or C₁-C₆ alkyl.

Claim 62 (previously presented): A compound of the formula

L¹ is -SO₂-, -S- or -S(O)-;

L² is -SO₂-;

R¹ is H, CH₃NH-, -CH₂CF₃, -NHC₃H₇, -NHC₂H₆, -NHC₄H₉, C₁-C₆ alkyl, -CF₃, -CH(CH₃)₂, thiophenyl, morpholinyl, cyclopropyl, cyclopentyl, benzyl, naphthyl,

-C(CH₃)₃, NHphenyl, 3,5-difluorophenyl, phenyl, N-cyclopentyl or N(CH₃)₂;


R² is H or -CH₃;

R⁴ is C₁-C₆ alkoxyl, cyclohexyl, cyclopentyl, phenyl, tolyl, C₃H₇, trifluoromethoxyphenyl, or -CH₃; and

each R⁴ may be optionally substituted with one to three substituents, which are the same or different and are independently selected from X;

R⁵ and R⁶ are independently H or -CH₃;

X is H, C₁-C₆ alkyl, C₁-C₆ alkoxy, halogen, -CF₃, -OCH₃, -OCF₃, -OCF₂H, -CH₃ or C₁-C₆ cycloalkyl;

Y is -SO₂- or  ;

Z is a covalent bond; or

R¹, Y, R² and Z taken together with the nitrogen atom form a morpholinyl group.

Claim 63 (previously presented): The compound according to claim 62 wherein

L¹ is -SO₂- or -CH₂-;

L² is -SO₂-;


R¹ is -CH₃ or -CF₃; and

R⁴ is phenyl, optionally substituted with one to three substituents which are the same or different, and are independently selected from the group consisting of C₁-C₆ alkyl, C₁-C₆ alkoxy, OH, -CF₃ and halogen.

Claim 64 (previously presented): The compound according to claim 63 wherein R⁴ is phenyl substituted with -OCH₃ or halogen.

Claim 65 (previously presented): The compound according to claim 64 wherein the halogen is selected from fluorine and chlorine.











Claim 66 (previously presented): The compound according to Claim 61 of the formula

















a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug;

wherein X and R⁴ are as shown in the table below:


	X	R ⁴
A	-OCH ₃	
B	-OCH ₃	
C	-OCF ₂ H	
F	-OCH ₃	
G	-CH ₃	
I	-OCH ₃	
J	-OCF ₃	

	X	R ⁴
L	Cl	
O	Cl	
Q	CH ₃	
Z	-OCH ₃	
AA	-OCH ₃	C ₃ H ₇
AB	-CF ₃	
AC	-CF ₃	
AF	-CF ₃	
AI	-CF ₃	
AK	Cl	
AQ	Cl	

	X	R ⁴
AU	Cl	
AX	Cl	C ₃ H ₇
BA	-OCF ₃	
BB	-OCF ₃	
BC	-OCF ₃	
BG	-OCH ₃	
CB	-CH ₃	
CE	Cl	
CW	OH	
CX	OH	










	X	R ⁴
DA	-OCF ₂ H	
FR	H	
FS	H	
FT	H	
FW	H	












Claim 67 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug;

wherein X and R⁴ are as shown in the table below:

	X	R ⁴
R	-CF ₃	
S	Cl	
W	Cl	
AE	-CF ₃	
AG	-CF ₃	
AH	-CF ₃	
AR	Cl	
AS	Cl	
BD	-OCF ₃	

BJ	-OCH ₃	
BZ	-CH ₃	
CA	-CH ₃	
FY	H	
FZ	H	
GI	Cl	
GJ	-OCH ₃	
GL	OH	
GM	OCH(CH ₃) ₂	
GN		













Claim 68 (previously presented): The compound according to Claim 61 of the formula














a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug;


wherein X, R¹ and R⁴ are as shown in the table below:

	X	R ¹	R ⁴
A	-OCH ₃	-CH ₃	
C	-OCF ₂ H	-CH ₃	
G	-CH ₃	-CH ₃	
L	Cl	-CH ₃	
R	-CF ₃	-CF ₃	

	X	R ¹	R ⁴
S	Cl	-CF ₃	
AB	-CF ₃	-CH ₃	
AT	Cl	-N(CH ₃) ₂	
BA	-OCF ₃	-CH ₃	
BD	-OCF ₃	-CF ₃	
BZ	-CH ₃	-CF ₃	
FS	H	-CH ₃	
FY	H	-CF ₃	
XXX		-CF ₃	
XXXII	-CN	-CF ₃	
XXXIII	-NH ₂	-CF ₃	


	X	R ¹	R ⁴
XXXIV		-CF ₃	
XXXIX	-CONH ₂	-CF ₃	
XXXX	-OCH ₃	-CF ₃	
XXXXI	-OH	-CF ₃	
XXXII		-CF ₃	
XXXIII		-CF ₃	
XXXIV	H ₃ C-CH ₂ -O-	-CF ₃	
XXXXV	H ₃ C-O-CH ₂ -CH ₂ -O-	-CF ₃	

Claim 69 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is -OCH₃ and R¹ is -CH₃.

Claim 70 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is -OCF₂H and R¹ is -CH₃.

Claim 71 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is -CH₃ and R¹ is -CH₃.

Claim 72 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R¹ is -CH₃.

Claim 73 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-\text{CF}_3$ and R^1 is $-\text{CF}_3$.

Claim 74 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R^1 is $-\text{CF}_3$.

Claim 75 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-\text{CF}_3$ and R^1 is $-\text{CH}_3$.

Claim 76 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R^1 is $-\text{N}(\text{CH}_3)_2$.

Claim 77 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is -OCF₃ and R¹ is -CH₃.

Claim 78 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is -OCF₃ and R¹ is -CF₃.

Claim 79 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is -CH₃ and R¹ is -CF₃.

Claim 80 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is H and R¹ is -CH₃.

Claim 81 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is H and R¹ is -CF₃.

Claim 82 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is cyclopropyl and R¹ is -CF₃.

Claim 83 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is cyclopropyl and R¹ is CH₃.

Claim 84 (previously presented): A pharmaceutical composition comprising an effective amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, according to claim 61 and a pharmaceutically acceptable carrier.


Claim 85 (previously presented): A pharmaceutical composition comprising an effective amount of a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug, according to claim 67 and a pharmaceutically acceptable carrier.

Claims 86-89 (canceled).

Claim 90 (previously presented): A pharmaceutical composition made by combining a compound, a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of a compound or of said prodrug, of Claim 61 and a pharmaceutically acceptable carrier therefor.


Claim 91-111 (canceled).

Claim 112 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-\text{OCH}_3$ and R^1 is $-\text{CH}_3$.

Claim 113 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-\text{OCF}_2\text{H}$ and R^1 is $-\text{CH}_3$.

Claim 114 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-\text{CH}_3$ and R^1 is $-\text{CH}_3$.

Claim 115 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R^1 is $-\text{CH}_3$.

Claim 116 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is -CF₃ and R¹ is -CF₃.

Claim 117 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R¹ is -CF₃.

Claim 118 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is -CF₃ and R¹ is -CH₃.

Claim 119 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is Cl and R¹ is -N(CH₃)₂.

Claim 120 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-\text{OCF}_3$ and R^1 is $-\text{CH}_3$.

Claim 121 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-\text{OCF}_3$ and R^1 is $-\text{CF}_3$.

Claim 122 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is $-\text{CH}_3$ and R^1 is $-\text{CF}_3$.

Claim 123 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is H and R^1 is $-\text{CH}_3$.

Claim 124 (previously presented): The compound according to Claim 61 of the formula




a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is H and R¹ is -CF₃.

Claim 125 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is cyclopropyl and R¹ is -CF₃.


Claim 126 (previously presented): The compound according to Claim 61 of the formula



a prodrug thereof, or a pharmaceutically acceptable salt, solvate or stereoisomer of the compound or of said prodrug; wherein X is cyclopropyl and R^1 is CH_3 .

Claim 127 (canceled).

Claim 128 (previously presented): A compound of the formula



or a pharmaceutically acceptable salt or stereoisomer thereof wherein:

R^1 is H, alkyl, halo C_{1-6} alkyl, cycloalkyl, cycloalkylNH-, arylalkyl, heterocycloalkyl, heteroaryl, $N(R^2)_2$, or NR^2 aryl, unsubstituted aryl or aryl substituted with one to three X;

R^2 is the same or different in each occurrence and is independently selected from H or C_{1-6} alkyl;

R^3 is H, C_{1-6} alkyl, Cl, F, CF_3 , OCF_2H , OCF_3 , OH or C_{1-6} alkoxy;

R^4 is H, C_1 - C_6 alkyl, C_1 - C_6 alkoxy, cycloalkyl, alkenyl, aryl, benzyl, arylNH-, cycloalkylNH-, $N(R^2)_2$, or NR^2 aryl, said alkyl, alkoxy, cycloalkyl, alkenyl, or aryl optionally substituted with one to three X;


R^5 is H or C_1 - C_6 alkyl;


R^6 is H or C_1 - C_6 alkyl; or

L^1 is $-S(O_2)-$, $-S(O)-$, or $-S-$;

L^2 is $-S(O_2)-$, $-S(O)-$, or $-S-$;

X is the same or different, and is independently selected from H, halogen, CF_3 , CN, OCF_2H , OCF_2CF_3 , OCF_3 , OR^2 , C_1 - C_6 alkyl, cycloalkyl, cycloalkoxy, C_1 - C_6 alkoxy, alkoxy C_1 - C_6 alkoxy, O-cycloalkyl, cycloalkylamino, cycloalkylalkoxy, heteroalkyl, $-OSO_2R^2$, $-COOR^2$, $-CON(R^2)_2$, NHR^2 , arylNH-, $N(R^2)_2$, or NR^2 aryl;


Y is a covalent bond, $-CH_2-$, $-S(O_2)-$, or ;

Z is a covalent bond, $-CH_2-$, $-S(O_2)-$ or ; or

Y, R^1 , Z and R^2 can be taken together with the nitrogen atom to form a heterocycloalkyl; with the proviso that if Y is a covalent bond, R^1 cannot form a N-N bond with the nitrogen atom; and

n is an integer of 0 to 4.

Claim 129 (previously presented): A compound of the formula



or a pharmaceutically acceptable salt or stereoisomer thereof wherein:

R^1 is H, alkyl, haloC₁-C₆ alkyl, cycloalkyl, cycloalkylNH-, arylalkyl, heterocycloalkyl, heteroaryl, N(R²)₂, or NR²aryl, unsubstituted aryl or aryl substituted with one to three X;

R^2 is the same or different in each occurrence and is independently selected from H or C₁-C₆ alkyl;

R^3 is H, C₁-C₆ alkyl, Cl, F, CF₃, OCF₂H, OCF₃, OH or C₁-C₆ alkoxy;


R^4 is H, C₁-C₆ alkyl, C₁-C₆ alkoxy, cycloalkyl, alkenyl, aryl, benzyl, arylNH-, cycloalkylNH-, N(R²)₂, or NR²aryl, said alkyl, alkoxy, cycloalkyl, alkenyl, or aryl optionally substituted with one to three X;

R^5 and R^6 taken together with the carbon atom to form a carbonyl group;

L^1 is -S(O₂)-, -S(O)-, or -S-;

L^2 is -S(O₂)-, -S(O)-, or -S-;

X is the same or different, and is independently selected from H, halogen, CF₃, CN, OCF₂H, OCF₂CF₃, OCF₃, OR², C₁-C₆ alkyl, cycloalkyl, cycloalkoxy, C₁-C₆ alkoxy, alkoxyC₁-C₆ alkoxy, O-cycloalkyl, cycloalkylamino, cycloalkylalkoxy, heteroalkyl, -OSO₂R², -COOR², NHR², arylNH-, N(R²)₂, or NR² aryl;

Y is a covalent bond, -CH₂-, -S(O₂)-, or ; and
n is an integer of 0 to 4.